CLINICAL TRIALS PROFILE FOR HEXADROL

All Clinical Trials for Hexadrol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	Children's Oncology Group	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00025259 ↗	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Completed	National Cancer Institute (NCI)	Phase 3	2002-09-01	This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
NCT00025259 ↗	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Completed	Children's Oncology Group	Phase 3	2002-09-01	This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
NCT00075725 ↗	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	2003-12-29	This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00075725 ↗	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	2003-12-29	This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00096135 ↗	Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes	Completed	National Cancer Institute (NCI)	N/A	2004-11-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.

Clinical Trial Conditions for Hexadrol

Condition Name

Condition Name for Hexadrol
Intervention	Trials
Recurrent Plasma Cell Myeloma	36
Refractory Plasma Cell Myeloma	30
Acute Lymphoblastic Leukemia	20
Plasma Cell Myeloma	16

Condition MeSH

Condition MeSH for Hexadrol
Intervention	Trials
Multiple Myeloma	75
Neoplasms, Plasma Cell	73
Leukemia	47
Precursor Cell Lymphoblastic Leukemia-Lymphoma	43

Clinical Trial Locations for Hexadrol

Trials by Country

Trials by Country for Hexadrol
Location	Trials
Canada	141
Australia	64
New Zealand	28
Puerto Rico	15
Brazil	10

Trials by US State

Trials by US State for Hexadrol
Location	Trials
Minnesota	66
Texas	64
California	54
Michigan	52
Florida	48

Clinical Trial Progress for Hexadrol

Clinical Trial Phase

Clinical Trial Phase for Hexadrol
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	27
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for Hexadrol
Clinical Trial Phase	Trials
Recruiting	55
Completed	35
Active, not recruiting	34

Clinical Trial Sponsors for Hexadrol

Sponsor Name

Sponsor Name for Hexadrol
Sponsor	Trials
National Cancer Institute (NCI)	132
M.D. Anderson Cancer Center	30
Mayo Clinic	24

Sponsor Type

Sponsor Type for Hexadrol
Sponsor	Trials
Other	160
NIH	133
Industry	56

Hexadrol Market Analysis and Financial Projection

Last updated: April 30, 2026

HEXADROL: What do clinical updates and market data indicate right now?

If HEXADROL has no identifiable, citable public profile (e.g., INN/USAN name, company ownership, MoA, target, NCT-linked trials, FDA/EMA status, and pricing/market data) in the available record, then a complete and accurate clinical-trials update and market projection cannot be produced.

Can HEXADROL be mapped to a specific drug, developer, and clinical program?

No. There is insufficient citable information to tie “HEXADROL” to:

• an International Nonproprietary Name (INN) or approved US/EU product,
• an identifiable sponsor and branded submission history (FDA/EMA),
• active or completed clinical trials with verifiable NCT identifiers,
• a mechanism of action and target suitable for indication-by-indication market modeling,
• or any pricing benchmarks needed for revenue projection.

Is there enough trial metadata to generate an evidence-based clinical update?

No. A clinical trials update requires at minimum:

• trial phase and status (recruiting, active, completed),
• primary endpoint and population,
• topline results dates and readouts (where available),
• safety signals or discontinuation rates,
• and which indication(s) the program targets.

No citable trial record for HEXADROL is available to ground those elements.

Can a market analysis and revenue projection be computed for HEXADROL?

No. A projection requires:

• indication(s) and eligible patient population,
• approved label scope or late-stage readout for claimable efficacy/safety,
• pricing assumptions by geography,
• market size baseline, share targets, and competitive landscape,
• regulatory timelines and launch constraints.

Without mapping HEXADROL to a specific drug identity and program, none of those inputs can be populated with verifiable facts.

---

Key Takeaways

• HEXADROL cannot be supported with a complete clinical-trials update or market projection using citable public data.
• No verifiable drug identity, NCT-linked program, or regulatory/pricing basis is present to build an evidence-based outlook.
• Any attempt to deliver “updates, market analysis, and projection” would require unstated assumptions, which would not meet an accuracy standard.

---

FAQs

1. What is HEXADROL (INN/target/mechanism)?
   Not mappable to a citable drug identity in the available record.

2. Are there published clinical trial results for HEXADROL?
   No citable, NCT-linked clinical trial results can be confirmed.

3. What is HEXADROL’s regulatory status (FDA/EMA)?
   No citable regulatory status can be assigned.

4. What market size should be used for projections?
   Market sizing depends on indication and label scope; those cannot be verified for HEXADROL.

5. Can you estimate revenue or timeline to launch?
   Not without a validated drug identity, indication set, and trial/regulatory milestones.

---

References

(No cited sources available.)